soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π Semaglutide cardiovascular outcomes align more
Pay in 4 interest-free payments of $5.58 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Sep 2 - Sep 7
























